Prevalence and antibiotic susceptibility of genital Mycoplasma hominis and Ureaplasma urealyticum in a university hospital in Turkey

Basit Öğe Kaydı
dc.authorid0000-0003-1514-1685
dc.authorid0000-0002-2860-1794
dc.authorid0000-0002-8929-6973
dc.contributor.authorKarabay, Oğuz
dc.contributor.authorTopçuoğlu, Ata
dc.contributor.authorKoçoglu, Esra
dc.contributor.authorGürel, Sebahat
dc.contributor.authorGürel, Hulusi
dc.contributor.authorİnce, Nevin K.
dc.date.accessioned2021-06-23T18:54:16Z
dc.date.available2021-06-23T18:54:16Z
dc.date.issued2006
dc.departmentBAİBÜ, Tıp Fakültesi, Dahili Tıp Bilimleri Bölümüen_US
dc.description.abstractThis study aimed to assess the colonization prevalence and antibiotic susceptibility of genital Ureaplasma urealyticum and Mycoplasma hominis in a teaching hospital, in Turkey. A total of 382 sexually active women with abnormal vaginal discharge were included in the study. Samples that were obtained with cotton swabs were microbiologically analyzed for U. urealyticum and M. hominis, together with antimicrobial susceptibility to doxycycline, ciprofloxacin, ofloxacin, erythromycin, josamycin, pristinamycin, and tetracycline. Ureaplasma urealyticum was detected in 185 (48.4%) cultures, and M. hominis in 17 (4.4%). Eight (2.1%) cultures were positive for both. Resistance of M. hominis to doxycycline, ciprofloxacin, ofloxacin, erytromycin, josamycin, pristinamycin and tetrascycline was 5.9%, 17.6%, 41.2%, 88.2%, 5.9%, 5.9% and 11.8%, respectively. Resistance to doxycycline, ciprofloxacin, ofloxacin, erytromycin, josamycin, pristinamycin and tetrascycline in U. urealyticum isolates was 1.6%, 40.5%, 58.4%, 54.0%, 1.6%, 8.1% and 13.5%, respectively. Both U. urealyticum (94.1%) and M. hominis (96.2) were most sensitive to josamycin, and most resistant to erytromycin (U. urealyticum 54.0%, M. hominis 88.2) and ofloxacin (U. urealyticum 58.4%, M. hominis 41.2%). As a result, the rate of U. urealyticum and M. hominis was found to be 48.4% and 4.4%, respectively. We conclude that doxycycline may be used in empirical treatment of genital tract infections in sexually active women.en_US
dc.identifier.endpage38en_US
dc.identifier.issn0390-6663
dc.identifier.issue1en_US
dc.identifier.pmid16761537en_US
dc.identifier.scopus2-s2.0-33646445309en_US
dc.identifier.scopusqualityQ4en_US
dc.identifier.startpage36en_US
dc.identifier.urihttps://hdl.handle.net/20.500.12491/4347
dc.identifier.urihttps://www.scopus.com/inward/record.uri?eid=2-s2.0-33646445309&partnerID=40&md5=b6dd25e34714c7f333b770b4f84ed654
dc.identifier.volume33en_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.institutionauthorKarabay, Oğuz
dc.language.isoenen_US
dc.relation.ispartofClinical and Experimental Obstetrics and Gynecologyen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectAntibiotic susceptibilityen_US
dc.subjectMycoplasma hominisen_US
dc.subjectPrevalenceen_US
dc.subjectUreaplasma urealyticumen_US
dc.titlePrevalence and antibiotic susceptibility of genital Mycoplasma hominis and Ureaplasma urealyticum in a university hospital in Turkeyen_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

Scopus İndeksli Yayınlar Koleksiyonu
Cerrahi Tıp Bilimleri Bölümü Koleksiyonu
Dahili Tıp Bilimleri Bölümü Koleksiyonu
PubMed İndeksli Yayınlar Koleksiyonu